Cargando…
Urinary podocalyxin is an early marker for podocyte injury in patients with diabetes: establishment of a highly sensitive ELISA to detect urinary podocalyxin
AIMS/OBJECTIVE: Nephropathy, a major complication of diabetes, is the leading cause of end-stage renal disease. Recent studies have demonstrated that podocyte injury is involved in the onset of and progression to renal insufficiency. Here, we describe a novel, highly sensitive ELISA for detecting ur...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3464371/ https://www.ncbi.nlm.nih.gov/pubmed/22854890 http://dx.doi.org/10.1007/s00125-012-2661-7 |
_version_ | 1782245417993371648 |
---|---|
author | Hara, M. Yamagata, K. Tomino, Y. Saito, A. Hirayama, Y. Ogasawara, S. Kurosawa, H. Sekine, S. Yan, K. |
author_facet | Hara, M. Yamagata, K. Tomino, Y. Saito, A. Hirayama, Y. Ogasawara, S. Kurosawa, H. Sekine, S. Yan, K. |
author_sort | Hara, M. |
collection | PubMed |
description | AIMS/OBJECTIVE: Nephropathy, a major complication of diabetes, is the leading cause of end-stage renal disease. Recent studies have demonstrated that podocyte injury is involved in the onset of and progression to renal insufficiency. Here, we describe a novel, highly sensitive ELISA for detecting urinary podocalyxin, a glycoconjugate on the podocyte apical surface that indicates podocyte injury, particularly in the early phase of diabetic nephropathy. METHODS: Urine samples from patients with glomerular diseases (n = 142) and type 2 diabetes (n = 71) were used to quantify urinary podocalyxin by ELISA. Urine samples were obtained from 69 healthy controls for whom laboratory data were within normal values. Podocalyxin was detected in urine by immunofluorescence, immunoelectron microscopy and western blotting. RESULTS: Morphologically, urinary podocalyxin was present as a vesicular structure; western blotting showed it as a positive band at 165–170 kDa. Levels of urinary podocalyxin were elevated in patients with various glomerular diseases and patients with diabetes. In patients with diabetes, urinary podocalyxin was higher than the cut-off value in 53.8% patients at the normoalbuminuric stage, 64.7% at the microalbuminuric stage and 66.7% at the macroalbuminuric stage. Positive correlations were observed between urinary podocalyxin levels and HbA(1c), urinary β(2) microglobulin, α(1) microglobulin and urinary N-acetyl-β-d-glucosaminidase, although urinary podocalyxin levels were not correlated with other laboratory markers such as blood pressure, lipid level, serum creatinine, estimated GFR or proteinuria. CONCLUSIONS/INTERPRETATION: Urinary podocalyxin may be a useful biomarker for detecting early podocyte injury in patients with diabetes. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00125-012-2661-7) contains peer-reviewed but unedited supplementary material, which is available to authorised users. |
format | Online Article Text |
id | pubmed-3464371 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Springer-Verlag |
record_format | MEDLINE/PubMed |
spelling | pubmed-34643712012-10-05 Urinary podocalyxin is an early marker for podocyte injury in patients with diabetes: establishment of a highly sensitive ELISA to detect urinary podocalyxin Hara, M. Yamagata, K. Tomino, Y. Saito, A. Hirayama, Y. Ogasawara, S. Kurosawa, H. Sekine, S. Yan, K. Diabetologia Article AIMS/OBJECTIVE: Nephropathy, a major complication of diabetes, is the leading cause of end-stage renal disease. Recent studies have demonstrated that podocyte injury is involved in the onset of and progression to renal insufficiency. Here, we describe a novel, highly sensitive ELISA for detecting urinary podocalyxin, a glycoconjugate on the podocyte apical surface that indicates podocyte injury, particularly in the early phase of diabetic nephropathy. METHODS: Urine samples from patients with glomerular diseases (n = 142) and type 2 diabetes (n = 71) were used to quantify urinary podocalyxin by ELISA. Urine samples were obtained from 69 healthy controls for whom laboratory data were within normal values. Podocalyxin was detected in urine by immunofluorescence, immunoelectron microscopy and western blotting. RESULTS: Morphologically, urinary podocalyxin was present as a vesicular structure; western blotting showed it as a positive band at 165–170 kDa. Levels of urinary podocalyxin were elevated in patients with various glomerular diseases and patients with diabetes. In patients with diabetes, urinary podocalyxin was higher than the cut-off value in 53.8% patients at the normoalbuminuric stage, 64.7% at the microalbuminuric stage and 66.7% at the macroalbuminuric stage. Positive correlations were observed between urinary podocalyxin levels and HbA(1c), urinary β(2) microglobulin, α(1) microglobulin and urinary N-acetyl-β-d-glucosaminidase, although urinary podocalyxin levels were not correlated with other laboratory markers such as blood pressure, lipid level, serum creatinine, estimated GFR or proteinuria. CONCLUSIONS/INTERPRETATION: Urinary podocalyxin may be a useful biomarker for detecting early podocyte injury in patients with diabetes. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s00125-012-2661-7) contains peer-reviewed but unedited supplementary material, which is available to authorised users. Springer-Verlag 2012-08-02 2012 /pmc/articles/PMC3464371/ /pubmed/22854890 http://dx.doi.org/10.1007/s00125-012-2661-7 Text en © The Author(s) 2012 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. |
spellingShingle | Article Hara, M. Yamagata, K. Tomino, Y. Saito, A. Hirayama, Y. Ogasawara, S. Kurosawa, H. Sekine, S. Yan, K. Urinary podocalyxin is an early marker for podocyte injury in patients with diabetes: establishment of a highly sensitive ELISA to detect urinary podocalyxin |
title | Urinary podocalyxin is an early marker for podocyte injury in patients with diabetes: establishment of a highly sensitive ELISA to detect urinary podocalyxin |
title_full | Urinary podocalyxin is an early marker for podocyte injury in patients with diabetes: establishment of a highly sensitive ELISA to detect urinary podocalyxin |
title_fullStr | Urinary podocalyxin is an early marker for podocyte injury in patients with diabetes: establishment of a highly sensitive ELISA to detect urinary podocalyxin |
title_full_unstemmed | Urinary podocalyxin is an early marker for podocyte injury in patients with diabetes: establishment of a highly sensitive ELISA to detect urinary podocalyxin |
title_short | Urinary podocalyxin is an early marker for podocyte injury in patients with diabetes: establishment of a highly sensitive ELISA to detect urinary podocalyxin |
title_sort | urinary podocalyxin is an early marker for podocyte injury in patients with diabetes: establishment of a highly sensitive elisa to detect urinary podocalyxin |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3464371/ https://www.ncbi.nlm.nih.gov/pubmed/22854890 http://dx.doi.org/10.1007/s00125-012-2661-7 |
work_keys_str_mv | AT haram urinarypodocalyxinisanearlymarkerforpodocyteinjuryinpatientswithdiabetesestablishmentofahighlysensitiveelisatodetecturinarypodocalyxin AT yamagatak urinarypodocalyxinisanearlymarkerforpodocyteinjuryinpatientswithdiabetesestablishmentofahighlysensitiveelisatodetecturinarypodocalyxin AT tominoy urinarypodocalyxinisanearlymarkerforpodocyteinjuryinpatientswithdiabetesestablishmentofahighlysensitiveelisatodetecturinarypodocalyxin AT saitoa urinarypodocalyxinisanearlymarkerforpodocyteinjuryinpatientswithdiabetesestablishmentofahighlysensitiveelisatodetecturinarypodocalyxin AT hirayamay urinarypodocalyxinisanearlymarkerforpodocyteinjuryinpatientswithdiabetesestablishmentofahighlysensitiveelisatodetecturinarypodocalyxin AT ogasawaras urinarypodocalyxinisanearlymarkerforpodocyteinjuryinpatientswithdiabetesestablishmentofahighlysensitiveelisatodetecturinarypodocalyxin AT kurosawah urinarypodocalyxinisanearlymarkerforpodocyteinjuryinpatientswithdiabetesestablishmentofahighlysensitiveelisatodetecturinarypodocalyxin AT sekines urinarypodocalyxinisanearlymarkerforpodocyteinjuryinpatientswithdiabetesestablishmentofahighlysensitiveelisatodetecturinarypodocalyxin AT yank urinarypodocalyxinisanearlymarkerforpodocyteinjuryinpatientswithdiabetesestablishmentofahighlysensitiveelisatodetecturinarypodocalyxin |